In this issue:
Intensifying therapy in PET-positive patients after upfront ASCT
Expert consensus: use of front-line anti-CD38 antibody therapy
IVIg prophylaxis mitigates serious infections in myeloma patients
Risk of infection with anti-BCMA bispecific therapy attenuated by IVIg therapy
Isatuximab + steroid an option for biochemical progression only relapsed/refractory disease
HOVON-143: Poor tolerability of ixazomib-based therapy thwarts efficacy in non-fit patients
Survival benefit to VRd vs Rd most pronounced in frail patients
Do patients with suboptimal response to induction derive a benefit from ASCT?
Stored cryopreserved autologous stem cells rarely used for salvage transplant
Characteristics of myeloma in adolescents and young adults
Please login below to download this issue (PDF)